About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNANCT02278107

Evaluation of a Lightweight Nasal Interface and Ventilator in Patients With Respiratory Disease

A preliminary study to evaluate a new nasal interface and portable ventilator system in comparison to standard oxygen therapy in patients with severe chronic lung disease.

Lead sponsor: New Aera, Inc•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

New Aera, Inc

An open-label, randomized, controlled, crossover study in patients with severe chronic lung disease to evaluate exercise tolerance compared to standard nasal cannula oxygen therapy.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Adult male or female (\> 18 years of age) with a diagnosis of severe-to-very severe chronic lung disease
•Participates in a qualified pulmonary rehabilitation program
•Requires constant flow oxygen of ≥ 2 LPM (liters per minute) during exercise
•Able and willing to sign the informed consent
•Ability to be fitted with the test nasal mask and to use the test ventilator system

Exclusion Criteria

•Requires \> 5LPM of constant flow to maintain SpO2\> 90% during exercise
•Reports having serious epistaxis within the last 14 days prior to enrollment
•Currently enrolled in another clinical study or has participated within 30 days of enrollment
•Has any condition or abnormality that in the opinion of the Investigators may compromise the participant's safety or the quality of the study data

Related studies

RECRUITINGPhase 1/2

Feasibility of Semaglutide in Advanced Lung Disease

NCT05746039 · Obesity, Interstitial Lung Disease, and more

RECRUITINGPhase 2

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

NCT06329401 · Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, and more

Effects of Oxygen Supplementation During the 6-Minute Walk Test in Chronic Respiratory Failure or Exertional Hypoxemia

NCT07451977 · Chronic Respiratory Failure, Hypoxemia, and more

Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid Arthritis

NCT07484243 · Rheumatoid Arthritis (RA), Rheumatoid Arthritis-Associated Interstitial Lung Disease, and more

RECRUITINGPhase 1

Nucleoside Therapy in Patients With Telomere Biology Disorders

NCT06817590 · Telomere Biology Disorders, Dyskeratosis Congenita, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 29, 2016Terms

Trial snapshot

StatusUNKNOWN

PhaseNA

Enrollment20

Start dateJul 2014

Last updatedFeb 29, 2016

Condition

Chronic Obstructive Lung Disease Interstitial Lung Disease

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 29, 2016Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions